NCT03758781已完成1 期
The IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical Activity
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Number of Participants Who Experience Dose Limiting Toxicities (DLTs)
研究概览
简要总结
This study is to determine the safety of IRX-2 Regimen combined with Nivolumab in patients with recurrent metastatic solid tumors. Researchers believe that this combination will have a tolerable safety profile and will increase the response rate in comparison to Nivolumab alone.
详细描述
The first phase of this trial is to establish the safety of IRX-2 Regimen combined with Nivolumab. The IRX-2 Regimen is a 21-day regimen of cyclophosophamide on Day 1 and subcutaneous IRX-2 injections for 10 days between Days 4 and 18. If no dose limiting toxicities (DLTs) are observed during the first 4 weeks of treatment, the enrollment will continue in a dose expansion phase. If there is a study treatment related DLT in 1 of 6 patients, the same dose will be investigated at the dose expansion cohorts. If study treatment related DLT is observed in 2 of 6 patients, accrual will be stopped and new dose levels or treatment sequences will be considered.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years of age
- •Participants must have histologically or cytologically confirmed renal cell carcinoma,urothelial carcinoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck or melanoma.
- •Participants must have recurrent or metastatic disease that is not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).
- •Must be willing and able to give informed consent and adhere to protocol therapy; written informed consent and any locally required authorization must be obtained from the participant prior to performing any protocol-related procedures, including screening evaluations
- •Prior exposure to PD-1/PD-L1 inhibitor monotherapy, or prior exposure to CTLA-4 inhibitor monotherapy is allowed.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- •Adequate normal organ and marrow function
- •Participants who are receiving therapeutic anti-coagulant therapy are eligible.
- •Palliative radiation therapy is allowed to non-target lesions at the discretion of the treating physician.
- •Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as outlined in RECIST version 1.
- •Life expectancy of greater than 3 months.
- •Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to treatment.
- •Body weight must be greater than 66 pounds.
排除标准
- •Prior exposure to a combination of IRX-2 regimen, PD-1/PD-L1 inhibitors and CTLA-4 inhibitors are excluded. Prior exposure to PD-1/PD-L1 inhibitors is allowed.
- •Radiation therapy with a curable intent within 30 days of first dose of study treatment is excluded. However, radiation therapy with a palliative intent is allowed to treat after 14 days from the last dose of radiation.
- •Any medical contraindications or previous therapy that would preclude treatment with the IRX-2 Regimen, or nivolumab.
- •Any unresolved toxicity Grade 2 or greater from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.
- •Participants with irreversible toxicity not reasonably expected to be exacerbated by treatment with IRX-2, or nivolumab may be included only after consultation with the study physician.
- •Active or prior documented autoimmune or inflammatory disorders
- •Current or prior use of immunosuppressive medication within 14 days before the first dose of study treatment. Some exceptions apply.
- •Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study treatment. Note: Local surgery of isolated lesions for palliative intent is acceptable.
- •History of allogenic organ transplantation.
- •Symptomatic cardiopulmonary disease, coronary artery disease, serious arrhythmia or chronic lung disease. Participants with these conditions who are stable with relatively minor symptoms and who are appropriate candidates for systemic treatments need not be excluded.
- •Myocardial infarction within the last 3 months.
- •Known infection with hepatitis B, hepatitis C, or HIV.
- •Signs or symptoms of systemic infection (use of antibiotics to treat superficial infection or contamination of tumor shall not, by itself, be considered evidence of infection).
- •Clinically significant gastritis or peptic ulcer disease
- •Stroke or other symptoms of cerebral vascular insufficiency within the last 3 months.
- •Allergy to ciprofloxacin (or other quinolones).
- •Previous diagnosis of invasive cancer from which the individual is not disease-free AND that has required treatment within the past 3 years, except for superficial skin, cervical cancer in-situ, or early stage prostate or bladder cancer (i.e. treatment with curative intent and long term disease-free expectations).
- •History of leptomeningeal carcinomatosis
- •Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
- •Female participants who are pregnant or breastfeeding or male or female participants of reproductive potential who are not willing to employ effective birth control from screening to 1 year after the last dose of study treatment.
研究组 & 干预措施
IRX-2 Regimen combined with Nivolumab
Experimental
IRX-2 Regimen (4 ml) combined with Nivolumab (240 mg)
干预措施: Nivolumab (Drug)
IRX-2 Regimen combined with Nivolumab
Experimental
IRX-2 Regimen (4 ml) combined with Nivolumab (240 mg)
干预措施: IRX 2 (Drug)
结局指标
主要结局
Number of Participants Who Experience Dose Limiting Toxicities (DLTs)
时间窗: Up to Day 28
A DLT is defined as any Grade 3 or higher toxicity which occurs during the DLT evaluation period of 4 weeks (during Cycle 1 Day 1 and Cycle 1 Day 28) and considered related to study treatment. Toxicity that is clearly and directly related to the primary disease or to another etiology is excluded.
次要结局
- Objective Response Rate(Up to 12 months)
- Progression Free Survival of combination therapy(Up to 12 months)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver CancerRecurrent Hepatocellular CarcinomaRefractory Liver CarcinomaStage IV Hepatocellular Carcinoma AJCC v8Stage IVA Hepatocellular Carcinoma AJCC v8Stage IVB Hepatocellular Carcinoma AJCC v8NCT03655002City of Hope Medical Center8
撤回
1 期
Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal CancerHuman Papillomavirus Positive Oropharyngeal Squamous Cell CarcinomaStage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7NCT03575234Emory University
已完成
1 期
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell CarcinomaSquamous Cell Carcinoma of the Head and NeckMetastatic Squamous Cell CarcinomaOral Cavity Squamous Cell CarcinomaOropharynx Squamous Cell CarcinomaParanasal Sinus Squamous Cell CarcinomaHypopharynx Squamous Cell CarcinomaLarynx Squamous Cell CarcinomaSquamous Cell CarcinomaNCT03381183H. Lee Moffitt Cancer Center and Research Institute19
已完成
1 期
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)Breast NeoplasmBreast Neoplasm, MaleTriple Negative Breast CancerNCT02950259Providence Health & Services16
终止
2 期
Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer PatientsBreast Cancer FemaleOvarian CancerGastric CancerNCT03342417ExcellaBio LLC5